Top in allergy/asthma: Chronic rhinosinusitis with nasal polyps; food allergy testing

In patients with chronic rhinosinusitis with nasal polyps, treatment with Dupixent was associated with improvements in sleep quality and decreased insomnia, according to a recent study.

Out of 29 study participants, 27 had altered sleep quality and 23 had insomnia at baseline. After 1 month of Dupixent (dupilumab; Regeneron/Sanofi) treatment, the number of patients with altered sleep quality fell to 20 and the number of patients with insomnia fell to 15. After 3 months, 16 patients had altered sleep quality and 11 had insomnia. It was the top story in allergy/asthma last week.

The second top story was about a presentation at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting on food allergy testing in children with eczema. According to the presenter, non-Hispanic Black children are significantly less likely to be tested for food allergies than white children.

Read these and more top stories in allergy/asthma below:

Dupilumab improves sleep among patients with chronic rhinosinusitis with nasal polyps

Sleep improved for patients with chronic rhinosinusitis with nasal polyps after a month of treatment with dupilumab, according to a study published in Annals of Allergy, Asthma & Immunology. Read more.

Black children with eczema less likely to undergo testing to confirm food allergy

Non-Hispanic Black children with eczema appeared significantly less likely to undergo skin and blood testing to confirm a food allergy compared with white children, according to results of a retrospective cohort study. Read more.

Epinephrine concentrations after injection decrease with greater BMI

There was a significant negative relationship between epinephrine exposure via injection and BMI, according to a presentation at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting. Read more.

VIDEO: Remote patient monitoring ‘a wonderful tool’ for asthma care

Remote patient monitoring and remote therapeutic monitoring can increase access to asthma care, Priya J. Bansal, MD, FAAAAI,FACAAI, said at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting. Watch video.

Decreased dupilumab dosing frequency associated with stable asthma control

Patients with well-controlled asthma who use dupilumab may tolerate a reduction in the frequency of their doses from every 2 weeks to every 4 weeks, according to a poster presented at the CHEST Annual Meeting. Read more.